INTRODUCTION {#s1}
============

According to the International Classification of Diseases (10th Revision) published by the World Health Organization, congenital hydrocephalus (CH) is characterized by an abnormal accumulation of cerebrospinal fluid (CSF) within the cerebral ventricles, which results from an imbalance between production and absorption \[[@R1]\]. Around 18−20 weeks of gestation, the first prenatal signs of hydrocephalus may be visible on ultrasound as the ''banana sign'', however, in some cases the hydrocephalus is only visible later in gestation. Although the accumulation of CSF in the majority of CH cases is reduced through the widespread use of CSF shunting, the fetus or infant often faces multiple surgical procedures resulting in significant morbidity \[[@R1], [@R2]\], which continues to be a worldwide public health burden. Obstruction of the cerebral aqueduct flow, Arnold-Chiari malformation, and Dandy-Walker malformation are the most common causes of CH \[[@R3]\]. Hydrocephalus is categorized as congenital or acquired; however, it is often difficult to distinguish between these entities in neonates because CH at birth may be secondary to another pathology \[[@R4]\]. In addition, hydrocephalus present at birth can remain subclinical until aging or trauma causes the disease to become symptomatic \[[@R4]--[@R7]\]. Therefore, the prevalence of CH remains poorly defined, not only because of the various definitions of CH between studies, but also the limited number of studies describing the differences between congenital and acquired hydrocephalus.

The prevalence of CH across time and regions ranges from 4.7 to 136.9 cases per 10,000 live births \[[@R8]--[@R18]\]. For example, Garne et al \[[@R9]\] observed eighty-seven congenital hydrocephalus cases (4.65 per 10,000 livebirths) during the period 1996--2003 from four European registries of congenital malformations (EUROCAT). For comparison, Fernell et al \[[@R18]\] found 13.69 per 1000 very preterm infants covering the birth years 1991--1994 in western Sweden. Furthermore, some studies have observed an increased prevalence of CH between the 1960s and 1990s, which might be attributed to the increased survival of extremely preterm infants \[[@R18], [@R19]\]. In contrast, several subsequent studies have suggested that the prevalence of CH has decreased in recent years \[[@R10], [@R13], [@R18]\]. This phenomenon has been thought to result from improved care of extremely preterm infants and the advent of folic acid supplementation or food fortification as well as the increasing rate of fetal termination after prenatal diagnosis of CH \[[@R20]\]. As compared to other countries, few studies have described the trends in the prevalence of CH in China, regardless of the observational period. For example, Wang et al \[[@R21]\] suggested that the prevalence of CH was 8.28 cases per 10,000 live births in China from 1988 to 1992. In addition, a decreasing trend was observed during this period \[[@R21]\]. In contrast, Dai et al. \[[@R8]\] reported 3012 perinatal cases of CH among 4,282,536 births in China from 1996 to 2004, yielding a prevalence of 7.03 cases per 10,000 live births. Notably, the annual prevalence of CH tended to increase during that period. However, the prevalence of CH over the past decade and whether a similar decreasing trend could still be observed in other cities remains unknown. As one of the most important provinces in China, Liaoning province covers an area of 145,900 km^2^ with a population of almost 42 million, which has greatly contributed to the development of China over the past few decades. Nevertheless, there has been no formal assessment of the prevalence of CH in this population. Therefore, the aim of the present study was to determine the prevalence of CH among infants in Liaoning province over a 10-year period from 2006 to 2015.

RESULTS {#s2}
=======

The numbers of live births in the 14 cities in Liaoning province during the 10-year observational period are presented in Table [1](#T1){ref-type="table"}. During this period, the overall number of live births was highest in 2014 (364,400) and lowest in 2015 (298, 437). In addition, when compared by city, Shenyang, the capital city of Liaoning province, had the largest number of live births in each year and Benxi had the smallest.

###### The number of live births in each city in Liaoning province, 2006 to 2015

  City                Year      Overall                                                                                   
  ------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- -----------
  Liaoning Province   306,734   341,432   330,414   321,353   307,826   304,079   353,108   321,171   364,400   298,437   3,248,954
  Shenyang            52,256    61,108    59,196    59,200    57,521    58,335    69,721    67,854    80,997    65,118    631,306
  Dalian              38,744    46,652    48,309    47,900    48,774    50,490    62,324    58,722    71,178    57,641    530,734
  Anshan              29,270    31,305    29,647    27,721    25,184    25,603    28,790    25,855    36,171    20,798    280,344
  Fushun              11,661    12,997    12,314    12,337    11,638    11,556    12,942    12,016    12,845    10,138    120,444
  Benxi               8620      9435      8759      8842      8696      8261      9440      8700      9857      7627      88,237
  Dandong             15,710    15,725    14,836    14,274    13,894    14,038    15,895    15,111    17,718    14,278    151,479
  Jinzhou             24,293    24,261    23,149    22,342    21,255    20,098    22,559    20,860    16,137    16,985    211,939
  Yingkou             16,987    18,924    19,667    19,070    17,947    18,484    21,309    14,224    21,684    16,515    184,811
  Fuxin               14,158    14,142    13,353    13,322    12,370    11,800    13,050    9662      9121      11,752    122,730
  Liaoyang            12,888    15,039    13,754    13,200    12,331    11,386    13,296    11,702    12,747    9251      125,594
  Panjing             9887      9669      10,134    9009      8800      8867      10,362    9644      8276      9197      93,845
  Tieling             21,263    20,298    21,456    19,854    18,421    16,945    18,938    14,960    17,389    15,269    184,793
  Chaoyang            28,669    30,980    31,168    30,574    27,837    27,207    31,236    29,919    30,646    26,083    294,319
  Huludao             22,328    30,897    24,672    23,708    23,158    21,009    23,246    21,942    19,634    17,785    228,379

The prevalence of CH in each city in Liaoning province is demonstrated in Figure [1](#F1){ref-type="fig"} and Figure [2](#F2){ref-type="fig"}. During the 10-year period of 2006--2015, 3008 cases of CH were detected among 3, 248, 954 live births (prevalence of 9.26 cases per 10,000 live births). Chaoyang (13.73 per 10,000 live births), Huludao (13.18 per 10,000 live births), and Fuxin (12.71 per 10,000 live births) recorded the highest rates of CH in Liaoning province. In contrast, Yingkou (6.06 per 10,000 live births), Dalian (6.27 per 10,000 live births), and Anshan (6.56 per 10,000 live births) recorded the lowest rates of CH.

![Number of newborns and congenital hydrocephalus cases from 2006 to 2015 on the basis of a population-based birth defect registry from Liaoning women and children\'s health hospital\
(**A**) newborns; (**B**) congenital hydrocephalus.](oncotarget-09-14472-g001){#F1}

![Prevalence of congenital hydrocephalus in each of 14 cities in Liaoning province from 2006 to 2015 on the basis of a population-based birth defect registry from Liaoning Women and Children\'s Health Hospital\
[www.d-maps.com/m/asia/china/liaoning/liaoning51.pdf](http://www.d-maps.com/m/asia/china/liaoning/liaoning51.pdf)](oncotarget-09-14472-g002){#F2}

The prevalence of CH in Liaoning province from 2006 to 2015 is presented in Figure [3](#F3){ref-type="fig"}. The overall prevalence significantly decreased from 14.64 to 3.18 cases per 10,000 live births, or 11.84% per year (*p* \< 0.01). Evaluation of the trend in CH prevalence demonstrated a decreasing trend in all cities of Liaoning province with a significant decrease in 10 (71.4%) of the 14 cities (Table [2](#T2){ref-type="table"} and Figure [4](#F4){ref-type="fig"}). Notably, the cities of Fushun, Shenyang, and Dalian contributed to more than one-third of the decreasing trend in the prevalence of CH in Liaoning province (Table [3](#T3){ref-type="table"}).
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###### Trends in CH prevalence in each city of Liaoning during 2006-2015

  CH         2006   2015    PC^†^ (%)   AC^†^ (%)   *P* value   95% CI             
  ---------- ------ ------- ----------- ----------- ----------- -------- --------- ----------------
  Overall    449    14.64   95          3.18        −78.25      −11.84   \< 0.01   −15.03, −8.52
  Shenyang   108    20.67   23          3.53        −82.91      −16.47   \< 0.01   −22.06, −10.49
  Dalian     44     11.36   9           1.56        −86.25      −14.53   0.01      −23.31, −4.75
  Anshan     24     8.20    4           1.92        −76.54      −9.34    0.04      −17.13, −0.80
  Fushun     18     15.44   2           1.97        −87.22      −19.27   \< 0.01   −28.06, −9.40
  Benxi      14     16.24   2           2.62        −83.85      −14.52   \< 0.01   −21.70, −6.70
  Dandong    18     11.46   4           2.80        −75.55      −12.98   \< 0.01   −19.35, −6.10
  Jinzhou    31     12.76   6           3.53        −72.32      −6.29    0.07      −12.76, 0.65
  Yingkou    5      2.94    4           2.42        −17.71      −4.78    0.42      −16.70, 8.84
  Fuxin      22     15.54   7           5.96        −61.67      −5.92    0.07      −12.00, 0.59
  Liaoyang   16     12.41   1           1.08        −91.29      −11.04   0.03      −19.62, −1.54
  Panjing    17     17.19   1           1.09        −93.68      −13.50   0.01      −22.20, −3.82
  Tieling    26     12.23   2           1.31        −89.29      −5.45    0.18      −13.58, 3.45
  Chaoyang   62     21.63   17          6.52        −69.86      −10.24   \< 0.01   −14.09, −6.22
  Huludao    44     19.71   13          7.31        −62.91      −6.01    0.04      −11.48, −0.20

AC, average change; CI, confidence interval; N/A, not available; PC, percent change.

^\*^ CH prevalence is expressed as the number of cases per 10,000 live births.

^†^ The percent change and average change in CH prevalence between 2006 and 2015 were calculated
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###### The relative contributions of decreasing trend of CH prevalence of each city in Liaoning province during 2006--2015

  City       Decreasing trend   
  ---------- ------------------ -------
  Shenyang   −0.18              11.19
  Dalian     −0.16              9.76
  Anshan     −0.10              6.09
  Fushun     −0.21              13.31
  Benxi      −0.16              9.75
  Dandong    −0.14              8.64
  Jinzhou    −0.07              4.04
  Yingkou    −0.05              3.05
  Fuxin      −0.06              3.79
  Liaoyang   −0.12              7.28
  Panjing    −0.15              9.02
  Tieling    −0.06              3.48
  Chaoyang   −0.11              6.72
  Huludao    −0.06              3.86

DISCUSSION {#s3}
==========

To the best of our knowledge, the present study is one of the few population-based reports of the prevalence of CH in China over the most recent decade. From 2006 to 2015, the prevalence of CH of Liaoning province significantly decreased from 14.64 to 3.18 cases per 10,000 live births due to decreasing trends observed in all 14 cities, although this trend did not reach statistical significance in all cities. Since the prevalence of CH remained relatively high in some cities, further preventive efforts are warranted to reduce the future risk of CH in these areas.

The results of the present study showed that the overall prevalence of CH in Liaoning province from 2006 to 2015 was 9.26 cases per 10,000 live births. Although geographic variation in the prevalence of this defect exists in different areas of different countries, compared to the results from recent studies performed in developed countries, these findings fall within the reported ranges of 2.5--10.4 cases per 10,000 live births \[[@R9]--[@R11], [@R13], [@R17], [@R19], [@R22]\]. In addition, a decreasing trend in the prevalence of CH was observed in these studies. Possible etiologies for this decline include implementation of folic acid supplementation, improved care of extremely preterm infants, and improved prenatal diagnosis leading to pregnancy termination \[[@R23]\]. Canada and the United States were the first countries to require mandatory fortification of enriched cereal grain products with 140 μg of folic acid per 100 g. Consequently, many studies have documented a reduction in these anomalies after implementation of this policy \[[@R24]\]. By mid-2012, a total of 67 counties required folic acid fortification of wheat flour (mandatory or voluntary programs), which affected approximately 2.2 billion people \[[@R24], [@R25]\]. However, fortification is uncommon in Asian and European countries, which may account for the regional differences in the prevalence of CH \[[@R26]\]. China initiated a nationwide folic acid supplementation program in 2009, which provides folic acid supplements, free of charge, to all women living in rural areas who plan to become pregnant \[[@R27]\]. The results of the present study showed that the prevalence of CH in 2012 to 2015 decreased dramatically from that of 2009 in the majority of the 14 surveyed cities, which may be partly attributable to the effects of this national policy. However, there was no significant decrease in the prevalence of CH in all 14 cities, suggesting that this phenomenon might be attributed to differences in the development of these cities and fewer women living in rural areas, as opposed to urban areas, of northern China had taken folic acid supplements before pregnancy \[[@R28]\]. Therefore, policymakers should pay more attention to this issue in these cities.

There were several strengths to this study. For example, the study data were collected from a population-based birth defect registry with good quality control \[[@R29]\] that included all 14 cities of Liaoning province over a relatively long time period (10 years) as well as the most recent data up to 2015, which comprehensively described the time trend and prevalence of CH in one of the most important provinces in China. However, this study is not without limitations. Firstly, when compared to the mature registry systems in developed countries, the Shenyang Women and Children Health Care Center began collecting information in 1992 and were inevitable to several common technical problems that could jeopardize the quality of the collected data \[[@R31]\], which might be responsible for under-reporting issue. Secondly, information pertaining to demographic factors of all live births in Liaoning province was not available, which hindered our ability to identify potential causes of the trends in the prevalence of CH. Furthermore, since the access on the data, we hardly analyzed distributions of CH prevalence by district/region of these cities. Thirdly, since the discharge diagnostic criteria of CH may differ between hospitals and individual coders, it is possible that these findings may be biased. Furthermore, it is difficult to know the degree to which this variation may be associated with other sources of variation \[[@R23]\]. Fourthly, the denominator of the prevalence of CH was the total number of births (live births and still births at a minimum of gestational week 28). Although the inclusion of induced and spontaneous fetal deaths before gestational week 28 would more closely approximate the prevalence of CH, it is very impractical, as these pregnancy outcomes are often inaccurately counted, as compared to live births and stillbirths \[[@R30]\]. In addition, as compared to the number of live births and stillbirths, the number of induced and spontaneous fetal deaths was small and thus unlikely to have greatly impacted the results \[[@R30]\]. Lastly, the maximal diagnosis time for CH cases was postnatal day 7 \[[@R29]\]. Hence, CH cases confirmed after postnatal day 7 were excluded from this study (*n* = 95). Therefore, the calculated prevalence of CH may be slightly lower than that over a longer period.

In summary, this population-based study provides recent and detailed evidence of the prevalence of CH between 2006 and 2015 in one of the most populated provinces in China. More importantly, the prevalence of CH remains high in some cities, which might draws attention to the need to improve the efficiency of periconceptional folic acid supplementation. Preventative efforts should be strengthened to reduce the risk of CH in areas with high prevalence.

MATERIALS AND METHODS {#s4}
=====================

Study population and data source {#s4_1}
--------------------------------

Liaoning Women and Children\'s Health Hospital is a primary obstetrical and gynecological hospitals as well as an official organization of government in Liaoning province that offers comprehensive healthcare to women and children. Data from 2006 to 2015 were retrieved from the maternal and child health certificate registry of Liaoning province maintained by this hospital. Hospital-delivered live birth and stillbirth infants in Liaoning province were all included in this registry as monitored subjects. The registry covers all 14 cities in the province (Shenyang, Dalian, Anshan, Fushun, Benxi, Dandong, Jinzhou, Yingkou, Fuxin, Liaoyang, Panjing, Tieling, Chaoyang, and Huludao), with approximately 42 million inhabitants. The maximal diagnosis time for a congenital malformation case was postnatal day 7 \[[@R29]\]. One hundred and nineteen city and counties institutions of maternal and child health in Liaoning province monthly uploaded the data to the Liaoning Women and Children\'s Health Hospital.

The detailed procedures of data collection are described in a previous report \[[@R29]\]. Briefly, a Birth Defect Registry Form was used to collect relevant information about infants with CH. We defined CH according to the World Health Organization\'s International Classification of Diseases, 10th Revision. Once a CH case was identified and confirmed at the monitored hospital, the mother of the infant was interviewed by a trained obstetric or pediatric specialist in order to complete the aforementioned registry form. Subsequently, the form was first submitted to the local maternal and child healthcare facility and then to the provincial maternal and child healthcare hospital, which was Liaoning Women and Children\'s Health Hospital. The data of these cases were reviewed and confirmed by a group of state-level experts in medical genetics and pediatrics \[[@R29]\].

All cases of CH were included for analysis. The prevalence of CH at birth is presented as the number of cases per 10,000 live births. The denominator was based exclusively on the total number of live births and data were obtained primarily from the database of Liaoning Women and Children\'s Health Hospital. For suspected cases of CH that were diagnosed through prenatal ultrasound scans, cases were ascertained after termination or postnatal examination. During the 10-year study period (2006--2015), a total of 3008 cases of CH were identified among a total of 3, 248, 954 live births.

Quality control of the data is described in detail elsewhere \[[@R29]\]. In brief, to ensure high quality data, disease diagnosis, data collection, data checking, and medical records were verified by an expert group at each level. In addition, an independent retrospective survey was conducted by experts to identify deficiencies and inaccuracies in the data \[[@R29]\]. This study protocol was approved by the Institutional Review Board of Liaoning Women and Children\'s Health Hospital and conducted in compliance with local and national regulations.

Statistical analysis {#s4_2}
--------------------

The prevalence of CH was calculated for ten 1-year time intervals from 2006 to 2015. In order to specifically assess time trends, a Poisson regression model was used to identify a line of best fit for the prevalence of CH by year, with year entered into the model as a continuous independent variable. The detail method of 95% confidence interval (CI) of the average change was described in previous report \[[@R31], [@R32]\]. Relative contributions to rate changes were calculated to provide the contributions of each city to the overall trend \[[@R31]--[@R33]\]. All analyses were conducted using IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY, USA). All statistical tests were two-sided and a probability (*P*) value of \< 0.05 was considered statistically significant.
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